Welcome back to Stockhouse Member Sign In
Sign in with one of the following accounts.
Send my password
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Use one of the following accounts.
My technical analysis strategy which is based on EMA looks like a buy. I stacked up at 1.20 Yesturday.
Orphan drug M & A in the U.S. for Ph 3 drug... Reuters) - Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva...
Since Bellus receives almost no coverage, below is what analysts in a Barron's article calculate Biogen's BIIB037 potential...ALZ...
http://www.bizjournals.com/boston/blog/bioflash/2015/04/alzheons-ceo-says-he-can-beat-biogen-with-the.html?ana=yahoo Biogen market cap...
My guess is that part of it would be distributed as a dividend and the rest would be used to push forward other projects in the pipeline.